Bimekizumab, a selective inhibitor of interleukin (IL)-17F and IL-17, has shown superior efficacy and safety in a 16 week trial in patients with active psoriatic arthritis who previously failed therapy with tumour necrosis factor-α (TNFi) inhibitors.

The BE COMPLETE study was a phase 3, randomised, double-blind, placebo-controlled trial, involving 400 patients with active adult-onset psoriatic arthritis. The primary endpoint was the ACR50 response rate at week 16 (non-responder imputation).